India notified the World Health Organization (WHO) on January 26, 2026, of two confirmed Nipah virus disease (NiVD) cases in West Bengal state, with laboratory confirmation received on January 13, 2026. Both confirmed cases were among healthcare workers — highlighting occupational risks in managing emerging infectious diseases. This represents the third Nipah virus outbreak reported in West Bengal, adding to a growing pattern of Nipah recurrence in India. The WHO assessed the overall risk as moderate at the sub-national (state) level and low at the national, regional, and global levels. As of the notification date, 196 contacts linked to the confirmed cases had been identified, traced, monitored, and tested — all contact tests returned negative results. Nipah virus (NiV) is a zoonotic virus — it spreads from animals (primarily fruit bats of the Pteropus genus, also known as flying foxes) to humans, and can also spread between humans through direct contact with infected bodily fluids. Nipah has a case fatality rate of 40-75%, making it one of the most dangerous known pathogens with pandemic potential. India has experienced multiple Nipah outbreaks since 2001 — in West Bengal (2001, 2007), and Kerala (2018, 2019, 2021, 2023, and July 2025 in Palakkad and Malappuram districts). There are no approved vaccines or treatments for Nipah as of 2026. The MoNaFO-77 monoclonal antibody treatment is under trial. The National Centre for Disease Control (NCDC) under MoHFW is the nodal agency for Nipah surveillance in India. The outbreak underscores the need for robust One Health frameworks — integrating human, animal, and environmental health — which is particularly relevant for Rajasthan given its dense human-livestock interface in rural areas.